Breast

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Retrieved on: 
Wednesday, March 20, 2024
Novartis, BNTX, Prostate cancer, Supervisory board, Survival, Science, BioNTech, COVID-19, Patient, Lung, Breast, Prostate, Cancer, Translation, Marketing, Development, Pharmaceutical industry

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.

Key Points: 
  • Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
  • Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access.
  • I believe its COVID-19 vaccine will only be the beginning of a series of approved products to follow in the years to come,” said Annemarie Hanekamp, designated Chief Commercial Officer at BioNTech.
  • Annemarie Hanekamp is a Dutch citizen and holds degrees in biomedical sciences as well as organizational leadership.

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
Tuesday, March 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

Ludwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Cell, Colorectal cancer, Life, Biomarker, Artificial intelligence, Breast, Cancer, AI, Messenger, Bladder cancer, Inflammation, Machine learning, Nike (company), OTC, Breast cancer, Vaccine

SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence cancer screening market.

Key Points: 
  • SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence cancer screening market.
  • The mRNA biomarkers uncovered by Ludwig are a sensitive dynamic genetic signal associated with cancer that opens the door for the company to participate in the emerging billion dollar diagnostic cancer screening market.
  • This test uses cutting edge machine learning artificial intelligence (AI) applied by Dr. Kyle Ambert PhD.
  • Dr. Ambert has extensive experience in data analytics, machine learning, artificial intelligence, and applied analytics.

Astra Plastic Surgery adds double board-certified facial plastic surgeon to acclaimed roster

Retrieved on: 
Thursday, March 14, 2024
Emory University, Head, Patient, Breast, American Academy, Learning, Surgeon, Physician, Neck, Dentistry

ATLANTA, March 14, 2024 (GLOBE NEWSWIRE) -- Astra Plastic Surgery, an acclaimed North Georgia-based cosmetic and reconstructive surgery practice, is welcoming Dr. Paul Daraei, a double board-certified facial plastic surgeon, to its staff of seasoned physicians and surgeons at its Alpharetta and Cumming locations.

Key Points: 
  • ATLANTA, March 14, 2024 (GLOBE NEWSWIRE) -- Astra Plastic Surgery, an acclaimed North Georgia-based cosmetic and reconstructive surgery practice, is welcoming Dr. Paul Daraei, a double board-certified facial plastic surgeon, to its staff of seasoned physicians and surgeons at its Alpharetta and Cumming locations.
  • Learning from prestigious nationally and internationally renowned surgeons, he completed a rigorous head and neck surgical residency at Emory University, followed by a fellowship in cosmetic facial plastic surgery at Rousso Facial Plastic Surgery in Birmingham, Alabama.
  • “At Astra Plastic Surgery, we provide innovative and personalized care that meets our patients’ aesthetic goals and inspires confidence,” says Dr. Christopher Killingsworth, founder and managing partner of Astra Plastic Surgery.
  • Astra Plastic Surgery was established in 2012, recognizing the need for both cosmetic and reconstructive surgery in the North Atlanta area.

Global Medical Aesthetics Market, 2023-2035: Dominance of Minimally Invasive Procedures - North America Leads, Asia-Pacific Shows Promise - ResearchAndMarkets.com

Retrieved on: 
Friday, April 5, 2024
Other Consumer, Medical Devices, Surgery, Women, LGBTQ+, Men, Consumer, Health, Cosmetics, Retail, Migraine, Type, Medical tourism, Elective surgery, COVID-19, Bariatric surgery, Hospital, Dermatology, IPL, Ageing, Breast, Cellulite, Safety, Market, Physician, FACE, Practitioner

The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.

Key Points: 
  • The market report highlights the efforts of medical aesthetics companies engaged in this growing segment of the cosmetic industry.
  • Presently, more than 200 medical aesthetics companies are engaged in offering various products and devices to fulfill aesthetic requirements of clients.
  • Additionally, medical aesthetic companies offer all types of invasive, non invasive and minimally invasive solutions to address the requirements of all end users, such as hospitals, medical aesthetic clinic and individuals in home care settings.
  • North America leads the medical aesthetics market, driven by advanced solutions, established companies, and high demand for cosmetic procedures.

Dr. Mia Talmor Joins the MTF Biologics Board of Directors

Retrieved on: 
Wednesday, March 27, 2024
Research, Surgery, Hospitals, Stem Cells, Other Health, Biotechnology, General Health, Health, Science, Other Science, MTF, Growth, Weill Cornell Medicine, Plastic, Woman, Today (American TV program), The New York Times, NewYork-Presbyterian Hospital, Trustee, Patient, Committee, Female, Breast, Rockefeller University, Plastic surgery, Aesthetic Plastic Surgery, Castle Connolly Medical, American College, Publication, American College of Surgeons, Society, Hospital, CBS, Division, Alfred Noble Prize, Bangladesh Technical Education Board, Multimedia, Education Committee, Public key certificate, Dentistry

MTF Biologics , a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing the science of tissue transplantation, has announced the appointment of Mia Talmor, MD , to the MTF Biologics Board of Directors.

Key Points: 
  • MTF Biologics , a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients, and advancing the science of tissue transplantation, has announced the appointment of Mia Talmor, MD , to the MTF Biologics Board of Directors.
  • View the full release here: https://www.businesswire.com/news/home/20240327225210/en/
    Dr. Mia Talmor, Professor of Clinical Surgery at The Weill Cornell Medical School and attending surgeon at New York Presbyterian Hospital, has joined the MTF Biologics Board of Directors.
  • (Photo: Business Wire)
    “We are honored to welcome Dr. Talmor to the MTF Board,” said William W. Tomford, MD, Chairman of the MTF Biologics Board of Directors.
  • Talmor brings a legacy of groundbreaking achievements in plastic surgery,” said Joe Yaccarino, MTF Biologics’ President and CEO.

Springer Nature and the Breast Cancer Research Foundation Announce the Rising Scholars: Breast Cancer Program for Early Career Researchers

Retrieved on: 
Tuesday, March 26, 2024
General Health, Oncology, Training, Consumer, Other Education, Continuing, Education, Publishing, Science, Women, Communications, Health, Other Science, Breast cancer, Breast Cancer Research Foundation, University, Master, Disease, Partnership, Breast, Nature Portfolio, Research, Mortality, Nature, Cancer, BCRF, Woman, Workforce, Springer Nature, Disaster recovery, DEI, Writing, Management

Springer Nature and the Breast Cancer Research Foundation (BCRF) today announced the Rising Scholars: Breast Cancer program, a partnership between Nature Portfolio and BCRF which provides Early Career Researchers (ECRs) in the field of cancer with additional resources for professional development and career preparedness.

Key Points: 
  • Springer Nature and the Breast Cancer Research Foundation (BCRF) today announced the Rising Scholars: Breast Cancer program, a partnership between Nature Portfolio and BCRF which provides Early Career Researchers (ECRs) in the field of cancer with additional resources for professional development and career preparedness.
  • The Rising Scholars: Breast Cancer program is the result of over a decade of partnership between Springer Nature and BCRF.
  • BCRF has been a phenomenal and consistent partner for Springer Nature and was the first nonprofit to work with Springer Nature in adopting our data research solutions.
  • The new Rising Scholars: Breast Cancer program will provide concrete qualitative and quantitative data as to the impact of such endeavors going forward.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Monday, March 25, 2024
Technology, Research, Medical Devices, Genetics, Biotechnology, Health, Pharmaceutical, Science, Consumer Electronics, Human Genome Project, WGS, Blood pressure, Genomics, Certification, Informatics, Genetic testing, Nucleus, Risk, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1, Vaccine

Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus Genomics , the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer’s entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina’s NovaSeq X Plus, the sequencing company’s newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

Cotchett, Pitre & McCarthy Files Lawsuit on Behalf of Residents of Maywood, CA, for Exposure to Cancer Causing Ethylene Oxide

Retrieved on: 
Monday, March 18, 2024
Professional Services, Legal, Environment, Bone marrow, Public health, Inhalation, National Cancer Institute, Breast, Ethylene oxide, Cancer, Leukemia, Ethylene, Aplastic anemia, Complaint, Atmosphere, Breast cancer, Partner, Superior court, Family, Stomach, Spice, Los Angeles Times, Lymphoma, Stomach cancer, Oil

Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.

Key Points: 
  • Cotchett, Pitre & McCarthy LLP filed a lawsuit on behalf of many longtime residents of Maywood, CA, next to Vernon, an industrial area, for their decades long exposure to cancer caused by carcinogenic Ethylene Oxide being released into the air.
  • Ethylene Oxide is used to sterilize medical equipment and spices but, during the process, some of the Ethylene Oxide escapes the facility into the surrounding air.
  • Ethylene Oxide is odorless and colorless, so nearby Maywood residents never knew it was in the air surrounding their homes.
  • According to the National Cancer Institute, and other protective health agencies around the world, Ethylene Oxide is associated with breast cancer, stomach cancer, lymphoma, and leukemia.

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ODD, Cancer, Research, PRMT5, Brain, Mutation, BRCA, NSCLC, NYU Langone Health, Breast, General counsel, Patient, GBM, Orphan, Collaboration, DNA, DevOps, MTAP, Sarcoma, Head, MTA, AACR, Glioblastoma, Clinical trial, PARP, Therapy, Drug development, ATM, ACS, Safety, Pharmacokinetics, Carcinoma, Corporate governance, FDA, American Chemical Society, Food, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
  • “In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials.
  • The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to TNG462 in December 2023 for the treatment of soft tissue sarcomas.
  • The increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.